| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-10-24 | BGB324 and pembrolizumab Company: | non-small cell lung cancer (NSCLC) | 2 | BergenBio (Norway) | Cancer - Oncology |
| 2017-10-23 | JNJ-4178 (AL-335) simeprevir, odalasvir | chronic Hepatitis C Virus (HCV) genotype 1-6 infection, with and without cirrhosis | 2b | Janssen Research & Development, a J&J company (USA - NJ) Medivir (Sweden) | Infectious diseases |
| 2017-10-23 | TG1050 (therapeutic vaccine) | chronic hepatitis B | 1-1b | Transgene (France) | Infectious diseases |
| 2017-10-19 | FR104 | rheumatoid arthritis, psoriasis | preclinical | Effimune (France) now OSE Immunotherapeutics (France) | Autoimmune diseases – Dermatological diseases - Inflammatory diseases - Rheumatic diseases |
| 2017-10-19 | ATA188 | progressive or relapsing-remitting multiple sclerosis | 1 | Atara Biotherapeutics (USA - CA) | Autoimmune diseases - Neurodegenerative diseases* |
| 2017-10-19 | DV281 | non-small cell lung cancer (NSCLC) | 1b | Dynavax (USA - CA) | Cancer - Oncology |
| 2017-10-19 | GED-0301 (mongersen) | Crohn disease | 3 | Celgene (USA - NJ) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2017-10-19 | bemcentinib (BGB324) | previously treated, locally advanced and unresectable or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC) | 2 | BergenBio (Norway) | Cancer - Oncology |
| 2017-10-18 | BMN 111 (vosoritide) | achondroplasia | 2 | Biomarin Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases |
| 2017-10-18 | PCM-075 (1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt) and Zytiga® (abiraterone acetate) | metastatic prostate cancer | preclinical | Trovagene (USA - CA) | Cancer - Oncology |
| 2017-10-18 | PV-10 and pembrolizumab | melanoma | 1b-2 | Provectus Pharmaceuticals (USA - TN) | Cancer - Oncology |
| 2017-10-18 | BMN 270 (valoctocogene roxaparvovec) | hemophilia A | 3 | Biomarin Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-10-18 | BMN 290 | Friedreich's Ataxia | Biomarin Pharmaceutical (USA - CA) | Rare diseases - Neurodegenerative diseases | |
| 2017-10-18 | AMT-130 (adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene) | Huntington's Disease | preclinical | Uniqure (The Netherlands) | Rare diseases - Genetic diseases - Neurodegenerative diseases |
| 2017-10-17 | VXM10 | preclinical | Vaximm (Germany) | Cancer - Oncology | |
| 2017-10-12 | AVR-RD-01 | Fabry disease | 1-2 | Avrobio (USA - MA) | Rare diseases - Genetic diseases - Lysosomal diseases |
| 2017-10-11 | HORA – PDE6B | retinitis pigmentosa due to a mutation in the PDE6B gene | 1-2 | Horama (France) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-10-09 | THR-317 | diabetic macular edema, diabetic retinopathy | preclinical | Thrombogenics (Belgium) | Ophtalmological diseases |
| 2017-10-06 | omadaycline | acute bacterial skin and skin structure infections (ABSSSI) | 3 | Paratek Pharmaceuticals (USA - MA) | Infectious diseases |
| 2017-10-02 | Effi-DEM | preclinical | OSE Immunotherapeutics (France) | Cancer - Oncology |
